ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

CGEN Compugen Ltd

2.58
0.04 (1.57%)
After Hours
Last Updated: 19:05:16
Delayed by 15 minutes

Period:

Draw Mode:

Volume 287,145
Bid Price 2.55
Ask Price 2.61
News -
Day High 2.625

Low
0.53

52 Week Range

High
3.0301

Day Low 2.50
Company Name Stock Ticker Symbol Market Type
Compugen Ltd CGEN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.04 1.57% 2.58 19:05:16
Open Price Low Price High Price Close Price Prev Close
2.54 2.50 2.625 2.58 2.54
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,118 287,145 $ 2.57 $ 737,479 - 0.53 - 3.0301
Last Trade Time Type Quantity Stock Price Currency
18:54:39 49 $ 2.60 USD

Compugen Ltd Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
229.34M 89.24M - 33.46M -18.75M -0.21 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Compugen News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No CGEN Message Board. Create One! See More Posts on CGEN Message Board See More Message Board Posts

Historical CGEN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.702.752.442.57258,385-0.12-4.44%
1 Month2.633.03012.342.70704,873-0.05-1.90%
3 Months1.993.03011.722.35707,7960.5929.65%
6 Months0.92993.03010.531.981,549,1571.65177.45%
1 Year0.713.03010.531.80965,7881.87263.38%
3 Years8.149.300.513.19944,840-5.56-68.30%
5 Years4.1619.900.516.72911,761-1.58-37.98%

Compugen Description

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its innovative immuno-oncology pipeline consists of four clinical stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

Your Recent History

Delayed Upgrade Clock